ReviewFrontiers in nutrition2025
Cholecalciferol (vitamin D3): efficacy, safety, and implications in public health.
Review in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Effects of Oral Cholecalciferol on Chronic Wound Healing in Patients with Vitamin D Insufficiency or Deficiency.Journal of multidisciplinary healthcare · 2025Trial
- Vitamin D as an Immuno-Endocrine Modulator: Discovering Its Role in Autoimmune Disorders and Host Defense Mechanisms.Journal of clinical medicine · 2026Review
- Updated perspectives on vitamin D deficiency, screening, supplementation and clinical guidance.Cardiovascular diabetology. Endocrinology reports · 2026Review
- Harnessing natural sunlight indoors: sensor-regulated therapeutic approach to enhance vitamin D status in humans.Scientific reports · 2026Article
- Role of Gut Microbiota in Bridging Vitamin D Deficiency and Type 2 Diabetes Mellitus Pathogenesis.Microorganisms · 2026Review
- Vitamin D in Infectious Diseases: A Narrative Review Focusing on COVID-19, Long COVID, and Influenza.Nutrients · 2026Review
- Vitamin D in Cardiovascular Medicine: From Molecular Mechanisms to Clinical Translation.Nutrients · 2026Review
- Association Among Serum Vitamin D Levels, Visual Field Alterations, and Optical Coherence Tomography Parameters: A Clinical Correlation Study.Life (Basel, Switzerland) · 2026Article
- Key regulators of lactation performance in Xinjiang Brown cattle and Chinese Holstein cattle unraveled by multi-omics integration.Frontiers in veterinary science · 2026Article
- Geometric Morphometrics Reveals That Alfacalcidol, but Not Cholecalciferol, Preserves Renal Corpuscle Architecture in Rheumatoid Arthritis in Rats.International journal of molecular sciences · 2025Article
- Impact of Adjunctive Air-Polishing on Periodontal Status in Patients with Low Vitamin DJournal of clinical medicine · 2025Article
- Therapeutic implications of vitamin D in leukemia: mechanistic and clinical perspectives.Medical oncology (Northwood, London, England) · 2025Review
- Metal-Based Nanomedicines for Inducing Programmed Cell Death to Enhance the Efficacy of Cancer Immunotherapy.International journal of nanomedicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitamin D₃ (cholecalciferol) is a fat-soluble secosteroid with essential roles in calcium-phosphorus metabolism, bone health, and an expanding range of extraskeletal processes. Upon synthesis in the skin via ultraviolet B exposure or ingestion from dietary sources, cholecalciferol is hydroxylated in the liver and kidneys to form its active metabolite, calcitriol (1,25-dihydroxyvitamin D), which exerts pleiotropic effects through vitamin D receptor (VDR)-mediated genomic and non-genomic pathways. This narrative review synthesizes evidence on the systemic effects of high-dose cholecalciferol on bone health, metabolism, cardiovascular and immune function, and its emerging roles in neurological, gastrointestinal, reproductive, oncologic, and psychiatric disorders. High-dose vitamin D₃ has demonstrated benefits in specific populations, including improved bone mineral density, immune homeostasis, glycemic control, and reduced inflammation. In patients with chronic kidney disease, cystic fibrosis, and inflammatory bowel disease, targeted supplementation has been associated with clinical improvements. Preclinical models support calcitriol's antiproliferative and neuroprotective functions, and its synergistic effects with chemotherapy, although large-scale randomized controlled trials (RCTs) have yielded mixed or inconclusive results, particularly in cancer, cardiovascular events, and cognitive decline. Methodological variability-such as inconsistent dosing regimens, baseline vitamin D status, and heterogeneous populations-limits definitive conclusions. While vitamin D supplementation is generally safe within recommended limits, excessive intake may cause hypercalcemia or nephrolithiasis, emphasizing the need for personalized strategies. Food fortification and targeted screening remain underutilized yet cost-effective public health interventions. Overall, vitamin D₃ represents a promising but complex therapeutic agent, necessitating further rigorously designed clinical trials to establish evidence-based guidelines for its use in diverse pathological conditions.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.